BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.

NCT Number	NCT07193511
Lead Sponsor	Avenzo Therapeutics, Inc.
Conditions	Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
Enrollment	355 participants
Start Date	2025-10-02
Primary Completion	2030-03 (estimated)
Study Completion	2030-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-05